{"id":"https://openalex.org/W4417481237","doi":"https://doi.org/10.1016/j.jval.2025.09.211","title":"CO109 Evaluating the Lifetime Incremental Value of Pharmaceutical Innovation: The Case of Non-Small Cell Lung Cancer","display_name":"CO109 Evaluating the Lifetime Incremental Value of Pharmaceutical Innovation: The Case of Non-Small Cell Lung Cancer","alternate_titles":[],"publication_year":2025,"publication_date":"2025-12-01","ids":{"openalex":"https://openalex.org/W4417481237","doi":"https://doi.org/10.1016/j.jval.2025.09.211"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2025.09.211","doi":"https://doi.org/10.1016/j.jval.2025.09.211","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jval.2025.09.211","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4417481237"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5120851228","display_name":"Panagiotis Therianos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I909854389","display_name":"London School of Economics and Political Science","ror":"https://ror.org/0090zs177","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I909854389"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Panagiotis Therianos","raw_affiliation_strings":["Medical Technology Research Group, London School of Economics and Political Science, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Technology Research Group, London School of Economics and Political Science, London, United Kingdom","institution_ids":["https://openalex.org/I909854389"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042397448","display_name":"A. Miracolo","orcid":"https://orcid.org/0000-0001-7764-6086","observed_orcids":["https://orcid.org/0000-0001-7764-6086"]},"institutions":[{"id":"https://openalex.org/I909854389","display_name":"London School of Economics and Political Science","ror":"https://ror.org/0090zs177","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I909854389"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Aurelio Miracolo","raw_affiliation_strings":["Medical Technology Research Group, London School of Economics and Political Science, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Technology Research Group, London School of Economics and Political Science, London, United Kingdom","institution_ids":["https://openalex.org/I909854389"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jennifer Gill","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I909854389","display_name":"London School of Economics and Political Science","ror":"https://ror.org/0090zs177","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I909854389"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jennifer Gill","raw_affiliation_strings":["Medical Technology Research Group, London School of Economics and Political Science, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Technology Research Group, London School of Economics and Political Science, London, United Kingdom","institution_ids":["https://openalex.org/I909854389"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062250544","display_name":"Panos G. Kanavos","orcid":"https://orcid.org/0000-0001-9518-3089","observed_orcids":["https://orcid.org/0000-0001-9518-3089"]},"institutions":[{"id":"https://openalex.org/I909854389","display_name":"London School of Economics and Political Science","ror":"https://ror.org/0090zs177","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I909854389"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Panos Kanavos","raw_affiliation_strings":["Medical Technology Research Group, London School of Economics and Political Science, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Technology Research Group, London School of Economics and Political Science, London, United Kingdom","institution_ids":["https://openalex.org/I909854389"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I909854389"],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"12","first_page":"S63","last_page":"S63"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9139999747276306},{"id":"https://openalex.org/keywords/pharmaceutical-innovation","display_name":"pharmaceutical innovation","score":0.9399999976158142},{"id":"https://openalex.org/keywords/customer-lifetime-value","display_name":"customer lifetime value","score":0.7739999890327454},{"id":"https://openalex.org/keywords/incremental-value","display_name":"incremental value","score":0.5329999923706055},{"id":"https://openalex.org/keywords/treatment-innovation","display_name":"treatment innovation","score":0.6639999747276306},{"id":"https://openalex.org/keywords/long-term-survival","display_name":"long-term survival","score":0.8399999737739563},{"id":"https://openalex.org/keywords/health-technology-assessment","display_name":"health technology assessment","score":0.5770000219345093},{"id":"https://openalex.org/keywords/treatment-strategy","display_name":"treatment options","score":0.5299999713897705}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7840999960899353},{"id":"https://openalex.org/C2779703844","wikidata":"https://www.wikidata.org/wiki/Q760125","display_name":"Reimbursement","level":3,"score":0.7053999900817871},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6434999704360962},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6371999979019165},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6086000204086304},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.5932999849319458},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5534999966621399},{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.5519999861717224},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.47290000319480896},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.45649999380111694},{"id":"https://openalex.org/C2779256446","wikidata":"https://www.wikidata.org/wiki/Q33959","display_name":"Nice","level":2,"score":0.444599986076355},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4431999921798706},{"id":"https://openalex.org/C2779220645","wikidata":"https://www.wikidata.org/wiki/Q21099132","display_name":"Alectinib","level":5,"score":0.4392000138759613},{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.40720000863075256},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.40549999475479126},{"id":"https://openalex.org/C108759981","wikidata":"https://www.wikidata.org/wiki/Q788590","display_name":"Authorization","level":2,"score":0.3781000077724457},{"id":"https://openalex.org/C2777589142","wikidata":"https://www.wikidata.org/wiki/Q6770899","display_name":"Marketing authorization","level":2,"score":0.3596999943256378},{"id":"https://openalex.org/C32220436","wikidata":"https://www.wikidata.org/wiki/Q2072214","display_name":"Personalized medicine","level":2,"score":0.35100001096725464},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.34150001406669617},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.33959999680519104},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32499998807907104},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.32359999418258667},{"id":"https://openalex.org/C2779903281","wikidata":"https://www.wikidata.org/wiki/Q6888026","display_name":"Modalities","level":2,"score":0.31859999895095825},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3172999918460846},{"id":"https://openalex.org/C3020340455","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Cancer drugs","level":3,"score":0.3151000142097473},{"id":"https://openalex.org/C2776291640","wikidata":"https://www.wikidata.org/wiki/Q2912517","display_name":"Value (mathematics)","level":2,"score":0.3009999990463257},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2847000062465668},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.28459998965263367},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.2777000069618225},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.275299996137619},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.26330000162124634},{"id":"https://openalex.org/C2992293740","wikidata":"https://www.wikidata.org/wiki/Q4781752","display_name":"Drug approval","level":3,"score":0.2603999972343445},{"id":"https://openalex.org/C108170787","wikidata":"https://www.wikidata.org/wiki/Q3951828","display_name":"Agency (philosophy)","level":2,"score":0.2574999928474426},{"id":"https://openalex.org/C163763905","wikidata":"https://www.wikidata.org/wiki/Q17075943","display_name":"Precision medicine","level":2,"score":0.25429999828338623},{"id":"https://openalex.org/C2778807442","wikidata":"https://www.wikidata.org/wiki/Q6152005","display_name":"Treatment of lung cancer","level":3,"score":0.2529999911785126},{"id":"https://openalex.org/C3020606620","wikidata":"https://www.wikidata.org/wiki/Q179661","display_name":"Treatment modality","level":2,"score":0.25290000438690186}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jval.2025.09.211","doi":"https://doi.org/10.1016/j.jval.2025.09.211","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jval.2025.09.211","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3025053020","https://openalex.org/W2785478765","https://openalex.org/W3044508023","https://openalex.org/W2545301421","https://openalex.org/W4390129383","https://openalex.org/W4223507637","https://openalex.org/W2432631849","https://openalex.org/W2399658845","https://openalex.org/W2094358619","https://openalex.org/W3028906699"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4417481237","counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-12-19T00:00:00"}
